# US 2021/0330604 A1 · Halogenated ether compounds and methods of inducing anesthesia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330604 A1
- Document ID: US20210330604A1
- Status: Published application
- Kind: A1
- Application number: 17/032,371
- Filed: 2020-09-25
- Published: 2021-10-28
- Earliest claimed: 2014-06-05
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Robert J. Brosnan
- Web page: https://patentgrep.com/patent/US20210330604A1

## CPC

- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of inducing anesthesia in a subject is provided. In some embodiments, the method provides administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of methyl-ethyl ethers, methyl-isopropyl ethers, and methyl-propyl ethers.

## Claims

### Claim at position 1

1-4. (canceled)

### Claim 5

A method for inducing anesthesia in a subject by potentiating GABAA receptors without inhibiting NMDA receptors, comprising administering to the subject via the respiratory system or via injection, an effective amount of a compound ethane, 1-bromo-1,1,2-trifluoro-2-(trifluoromethoxy)- (CAS #2356-55-0), thereby inducing anesthesia in the subject by potentiating GABAA receptors without inhibiting NMDA receptors.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject is a mammal.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject is a human.

### Claim 8 (depends on 5)

The method of claim 5, wherein the step of inducing anesthesia includes inducing a state selected from the group consisting of analgesia, tranquilization, sedation, amnesia, a hypnotic state, and a state of insensitivity to noxious stimulation.

### Claim at position 6

9-16. (canceled)

### Claim 17

A method for inducing anesthesia in a subject, the method comprising administering to the subject via the respiratory system or via injection, an effective amount of a compound or a mixture of compounds selected from the group consisting of a halogenated methyl-ethyl ether, a halogenated methyl-isopropyl ether, and a halogenated methyl-propyl ether, wherein the halogenated methyl-ethyl ether is selected from the group consisting of: Ethane, 1-(chlorodifluoromethoxy)-1,1,2,2,2-pentafluoro- (CAS #276640-96-1); Ethane, 2-bromo-1,1,1-trifluoro-2-(trifluoromethoxy)- (CAS #84011-04-1); Ethane, 1-bromo-1,2,2-trifluoro-1-(trifluoromethoxy)- (CAS #885275-60-5); Ethane, 2-bromo-1,1,2-trifluoro-1-(trifluoromethoxy)-(CAS #84011-03-0); Ethane, 1-bromo-1,1,2-trichloro-2-(trifluoromethoxy)- (CAS #2356-55-0): Ethane, 2-chloro-1,1,2-trifluoro-1-(trifluoromethoxy)- (CAS #879885-11-7); Ethane, 2-chloro-1,1,1-trifluoro-2-(trifluoromethoxy)- (CAS #,94720-92-0); Ethane, 1-chloro-1,1,2-trifluoro-2-(trifluoromethoxy)- (CAS #2356-59-4); Ethane, 1-chloro-1,1-difluoro-2-(trifluoromethoxy)-(CAS #1645-80-3); Ethane, 1-chloro-1,2-difluoro-2-(trifluoromethoxy)-, (R*,S*)- (9CI) (CAS #84011-29-0); Ethane, 1-chloro-1,2-difluoro-2-(trifluoromethoxy)-(R*,R*)- (9CI) (CAS #84011-28-9); Ethane, 1-chloro-1,2-difluoro-2-(trifluoromethoxy)- (CAS #54362-39-9); Ethane, 1-chloro-2,2-difluoro-1-(trifluoromethoxy)- (CAS #33445-33-9); and mixtures thereof; wherein the halogenated methyl-isopropyl ether is selected from the group consisting of: Propane, 1-chloro-1,1,2,3,3,3-hexafluoro-2-(trifluoromethoxy)- (CAS #41255-97-4); Propane, 1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethoxy)- (CAS #60901-74-8); Propane, 1,1,1,3,3,3-hexafluoro-2-(trifluoromethoxy)- (CAS #162401-05-0); Propane, 2- (difluoromethoxy)-1,1,1,2,3,3-hexafluoro-(CAS #233258-12-3), and mixtures thereof; and wherein the halogenated methyl-propyl ether is selected from the group consisting of: Propane, 1,1,2,2,3,3-hexafluoro-1-methoxy-(CAS #160620-20-2); Propane, 1,1,1,2,2,3-hexafluoro-3-methoxy- (CAS #123202-00-6); Propane, 1,1,1,2,3,3-hexafluoro-3-(fluoromethoxy)- (CAS #60598-14-3); Propane, 3-(difluoromethoxy)-1,1,1,2,2-pentafluoro- (CAS #56860-81-2); Propane, 1,1,1,2,2-pentafluoro-3-(fluoromethoxy)- (CAS #1515-13-5); and mixtures thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject is a mammal.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject is a human.

### Claim 20 (depends on 17)

The method of claim 17, wherein the step of inducing anesthesia includes inducing a state selected from the group consisting of analgesia, tranquilization, sedation, amnesia, a hypnotic state, and a state of insensitivity to noxious stimulation.

### Claim 21 (depends on 17)

The method of claim 17, wherein the compound potentiates GABAA receptors, but does not inhibit NMDA receptors.
